Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
UBX Stock Forecast 2026-2027
$0.06
Current Price
$965,604
Market Cap
Buy 1
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to UBX Price Targets
+10,595.2%
To High Target of $6.00
+3,465.1%
To Median Target of $2.00
+1,682.5%
To Low Target of $1.00
UBX Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
-40.0%
1 Year Change
0.0%
Year-to-Date Change
-98.2%
From 52W High of $3.10
+15.2%
From 52W Low of $0.05
📊 TOP ANALYST CALLS
Did UBX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if UNITY is one of their latest high-conviction picks.
Latest UBX Stock Price Targets & Analyst Predictions
Wall Street analysts covering UBX have a neutral consensus with a median price target of $2.00 (ranging from $1.00 to $6.00). The overall analyst rating is Buy (7.3/10). Currently trading at $0.06, the median forecast implies a 3,465.1% upside. This outlook is supported by 1 Buy, 2 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
UBX Analyst Ratings
1
Buy
2
Hold
0
Sell
UBX Price Target Range
Low
$1.00
Average
$2.00
High
$6.00
Current: $0.06
Latest UBX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for UBX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
Unity Biotechnology Inc. (UBX) Competitors
The following stocks are similar to UNITY based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Unity Biotechnology Inc. (UBX) Financial Data
Unity Biotechnology Inc. has a market capitalization of $965,604 with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -231.3%.
Valuation Metrics
Market Cap
$965,604
Enterprise Value
$8.43M
P/E Ratio
0.0x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+1,754.0%
Current Ratio
1.9x
Debt/Equity
-110.3x
ROE
-231.3%
ROA
-38.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Unity Biotechnology Inc. (UBX) Business Model
About Unity Biotechnology Inc.
What They Do
Develops therapeutics targeting aging-related diseases.
Business Model
Unity Biotechnology generates revenue through the development of innovative therapeutics aimed at delaying age-related diseases. By focusing on cellular senescence, the company creates targeted therapies that address conditions affecting the aging population, potentially leading to partnerships with pharmaceutical companies and licensing deals.
Additional Information
As the global population ages, Unity Biotechnology's focus on senescence biology positions it uniquely within the biotechnology sector. The company's work aims not only to extend healthspan but also to improve the overall quality of life for older adults, making it a significant player in addressing the needs of a growing demographic.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
16
CEO
Dr. Anirvan Ghosh Ph.D.
Country
United States
IPO Year
2004
Website
unitybiotechnology.comUnity Biotechnology Inc. (UBX) Latest News & Analysis
Latest News
Quick Summary
UNITY Biotechnology (NASDAQ: UBX) will present 36-week data from its ASPIRE Phase 2B study at the ARVO 2025 Annual Meeting in Salt Lake City from May 4-8.
Why It Matters
The upcoming presentation of Phase 2B study data by UNITY Biotechnology could significantly impact its stock price and investor sentiment, reflecting progress in aging-related therapeutics.
Source: GlobeNewsWire
Market Sentiment:
Neutral
UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates
1 year ago
Quick Summary
UNITY Biotechnology, Inc. (NASDAQ:UBX) reported its Q1 financial results for 2025, focusing on therapeutics aimed at aging-related diseases. Further details were not provided.
Why It Matters
UNITY's financial results can impact stock performance and investor sentiment, highlighting its progress in aging-related therapeutics, crucial for market positioning and potential revenue growth.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Unity Biotechnology Unveils Mixed Data From Study For Diabetes-Related Blindness, Stock Falls
1 year ago
Quick Summary
Unity Biotechnology, Inc. (UBX) shares dropped significantly on Monday following the release of results from its latest study.
Why It Matters
The drop in Unity Biotechnology's stock indicates negative investor sentiment following disappointing study results, potentially affecting future funding and market confidence in the company.
Source: Benzinga
Market Sentiment:
Negative
Quick Summary
UBX1325 showed comparable vision gains to aflibercept in a difficult-to-treat patient group, with +5.2 and +5.5 letter gains at 24 and 36 weeks, respectively. An investor call is scheduled for March 24.
Why It Matters
UBX1325 shows promising results in treating vision loss, potentially positioning it as a competitive alternative to aflibercept. The upcoming investor call may impact stock prices and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
UNITY Biotechnology's stock dropped 29% after its mid-stage study of UBX1325 for diabetic macular edema failed to meet the primary goal's statistical significance.
Why It Matters
UNITY Biotechnology's 29% stock drop reflects investor concerns over the failed DME study, signaling potential setbacks in product development and future revenue.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
UNITY Biotechnology (NASDAQ: UBX) will host a virtual investor event on March 24, 2025, at 8:00 AM ET to discuss its aging-related therapeutics.
Why It Matters
UNITY's upcoming investor event could signal new developments or data releases, which may impact stock performance and investor sentiment around its aging-related therapeutics.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About UBX Stock
What is Unity Biotechnology Inc.'s (UBX) stock forecast for 2027?
Based on our analysis of 0 Wall Street analysts, Unity Biotechnology Inc. (UBX) has a median price target of $2.00. The highest price target is $6.00 and the lowest is $1.00.
Is UBX stock a good investment in 2027?
According to current analyst ratings, UBX has 1 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.06. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for UBX stock?
Wall Street analysts predict UBX stock could reach $2.00 in the next 12 months. This represents a 3,465.1% increase from the current price of $0.06. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Unity Biotechnology Inc.'s business model?
Unity Biotechnology generates revenue through the development of innovative therapeutics aimed at delaying age-related diseases. By focusing on cellular senescence, the company creates targeted therapies that address conditions affecting the aging population, potentially leading to partnerships with pharmaceutical companies and licensing deals.
What is the highest forecasted price for UBX Unity Biotechnology Inc.?
The highest price target for UBX is $6.00 from at , which represents a 10,595.2% increase from the current price of $0.06.
What is the lowest forecasted price for UBX Unity Biotechnology Inc.?
The lowest price target for UBX is $1.00 from at , which represents a 1,682.5% increase from the current price of $0.06.
What is the overall UBX consensus from analysts for Unity Biotechnology Inc.?
The overall analyst consensus for UBX is neutral. Out of 0 Wall Street analysts, 1 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $2.00.
How accurate are UBX stock price projections?
Stock price projections, including those for Unity Biotechnology Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 16, 2026 4:48 PM UTC